ALCAM/CD166 Products

Description

Activated leukocyte cell adhesion molecule (ALCAM), also known as CD166, is a surface glycoprotein belonging to the immunoglobulin superfamily (1, 2). ALCAM, along with MCAM and BCAM/Lu, form a small subgroup of adhesion molecules involved in tissue development and maintenance, neurogenesis, and regulation of immune responses (3). Mature human ALCAM consists of an extracellular domain (ECD) containing 2 IgV and 3 IgC domains, a transmembrane domain, and a short cytoplasmic domain (1, 2). Within the ECD, human ALCAM shares 93% amino acid sequence identity with both mouse and rat ALCAM. An isoform of ALCAM with a shorter stalk region in the ECD is known to exist and is associated with higher shedding tendency and decreased cell adhesion (2). Initially found expressed on activated leukocytes, ALCAM expression has been detected in a wide variety of tissues and cells (3, 4). In addition to cell adhesion, other ALCAM functions include leukocyte migration across the blood brain barrier, T-cell activation, and osteogenesis, (2, 5, 6). Overexpression of ALCAM is often associated with poor prognosis in various human tumors, such as bladder cancer, prostate cancer, melanoma, and liver cancer (2, 7). Our Avi-tag Biotinylated Recombinant Human ALCAM features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

Bioinformatics

Product By Gene ID	214
Alternate Names	activated leucocyte cell adhesion molecule activated leukocyte cell adhesion moleculeFLJ38514 ALCAM CD166 antigen CD166 MEMDMGC71733